RxDoctor Payments Data

Christopher Smith

Interventional Pain Medicine · Corvallis, ORNPI 1053744524

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 26 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by AbbVie at 23.3% of the total. That places this record below the midpoint for interventional pain medicine clinicians in OR, where the typical reported total is $8,094.

$414in general payments, 2019–2025

Across 26 payments — averaging $15.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$97
  • Amgen$71
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$67
  • Biohaven Pharmaceuticals, Inc.$64
  • Boston Scientific$55
  • Biodelivery Sciences International, Inc.$49
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$414100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$414 in reported general payments places this provider in the 15th percentile of 22 interventional pain medicine providers in Oregon.

See all interventional pain medicine providers in Oregon

Medicare billing

Part B allowed, 2024
$63,550
Medicare patients
276
Services billed
853

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate31$36,907
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,152$30,870
BelbucaBuprenorphine Hcl33$30,539
Buprenorphine91$23,573
Oxycodone Hcl959$19,085
Aimovig AutoinjectorErenumab-Aooe24$17,811
Xtampza ErOxycodone Myristate39$17,699
OxycontinOxycodone Hcl43$14,779
LinzessLinaclotide20$13,137
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen488$10,618
Morphine Sulfate ErMorphine Sulfate316$8,413
Fentanyl70$8,157
Gabapentin431$8,070
LyricaPregabalin12$6,926
Pregabalin353$4,953

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$97$13,13720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 22 interventional pain medicine providers in Oregon.

Other interventional pain medicine in Corvallis

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →